Literature DB >> 32096707

Intraoperative Complications of Endovascular Treatment of Intracranial Aneurysms with Coiling or Balloon-assisted Coiling in a Prospective Multicenter Cohort of 1088 Participants: Analysis of Recanalization after Endovascular Treatment of Intracranial Aneurysm (ARETA) Study.

Laurent Pierot1, Coralie Barbe1, Huu An Nguyen1, Denis Herbreteau1, Jean-Yves Gauvrit1, Anne-Christine Januel1, Fouzi Bala1, Pierre-Olivier Comby1, Hubert Desal1, Stéphane Velasco1, Mohamed Aggour1, Emmanuel Chabert1, Jacques Sedat1, Denis Trystram1, Gaultier Marnat1, Sophie Gallas1, Georges Rodesch1, Frédéric Clarençon1, Sébastien Soize1, Matthias Gawlitza1, Laurent Spelle1, Philip White1.   

Abstract

Background Thromboembolic events and intraoperative rupture are the most frequent neurologic complications of intracranial aneurysm coiling. Their frequency has not been evaluated in recent series. Purpose To provide an analysis of complications, clinical outcome, and participant and aneurysm risk factors after aneurysm coiling or balloon-assisted coiling within the Analysis of Recanalization after Endovascular Treatment of Intracranial Aneurysm, or ARETA, cohort. Materials and Methods Sixteen neurointerventional departments prospectively enrolled participants treated for ruptured and unruptured aneurysms between December 2013 and May 2015. Participant demographics, aneurysm characteristics, and endovascular techniques were recorded. Data were analyzed from participants within the overall cohort treated with coiling or balloon-assisted coiling for a single aneurysm. Rates of neurologic complications were analyzed, and associated factors were studied by using univariable analyses (Student t test, χ2 test, or Fisher exact test, as appropriate) and multivariable analyses (logistic regressions). Results A total of 1088 participants (mean age ± standard deviation, 54 years ± 13; 715 women [65.7%]) were analyzed. Thromboembolic events and intraoperative rupture were reported in 113 of 1088 participants (10.4%) and 34 of 1088 participants (3.1%), respectively. Poor clinical outcome (defined as modified Rankin Scale score of 3-6) was reported in 29 of 113 participants (25.7%) with thromboembolic events and in 11 of 34 participants (32.4%) with intraoperative rupture (P = .44). Factors associated with thromboembolic events were female sex (odds ratio [OR], 1.7; 95% confidence interval [CI]: 1.1, 2.8; P = .02) and middle cerebral artery location (OR, 1.9; 95% CI: 1.2, 3.0; P = .008). Factors associated with intraoperative rupture were anterior communicating artery location (OR, 2.2; 95% CI: 1.1, 4.7; P = .03) and small aneurysm size (OR, 3.0; 95% CI: 1.5, 6.3; P = .003). Conclusion During aneurysm coiling or balloon-assisted coiling, thromboembolic events were more frequent than were intraoperative rupture. Both complications were associated with poor clinical outcome in a similar percentage of participants. Risk factors for thromboembolic events were female sex and middle cerebral artery location. Risk factors for intraoperative rupture were small aneurysm size and anterior cerebral or communicating artery location. © RSNA, 2020.

Entities:  

Year:  2020        PMID: 32096707     DOI: 10.1148/radiol.2020191842

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Three-dimensional printing-assisted precision microcatheter shaping in intracranial aneurysm coiling.

Authors:  Xiaowen Song; Hancheng Qiu; Wenjun Tu; Shuo Wang; Yong Cao; Chen Li; Shuo Yang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2022-01-06       Impact factor: 3.042

Review 2.  The Woven Endobridge as a treatment for acutely ruptured aneurysms: A review of the literature.

Authors:  William Crinnion; Pervinder Bhogal; Hegoda Levansri Dilrukshan Makalanda; Ken Wong; Adam Arthur; Christophe Cognard; Hans Henkes; Dave Fiorella; Laurent Pierot
Journal:  Interv Neuroradiol       Date:  2021-01-28       Impact factor: 1.764

3.  Safety and efficacy of complete versus near-complete coiling in treatment of intracranial aneurysms.

Authors:  Guogdong Zhang; Yongsheng Liu; Yongjian Liu; Mingyi Wang; Ke Li; Feng Wang
Journal:  J Interv Med       Date:  2020-07-09

4.  CLinical Assessment of WEB device in Ruptured aneurYSms (CLARYS): results of 1-month and 1-year assessment of rebleeding protection and clinical safety in a multicenter study.

Authors:  Laurent Spelle; Denis Herbreteau; Jildaz Caroff; Xavier Barreau; Jean-Christophe Ferré; Jens Fiehler; Anne-Christine Januel; Vincent Costalat; Thomas Liebig; Romain Bourcier; Markus Möhlenbruch; Joachim Berkefeld; Werner Weber; Cristian Mihalea; Léon Ikka; Augustin Ozanne; Christophe Cognard; Ana Paula Narata; Richard Edwige Bibi; Jean-Yves Gauvrit; Hélène Raoult; Stéphane Velasco; Jan-Hendrik Buhk; Vanessa Chalumeau; Maxim Bester; Hubert Desal; Richard du Mesnil de Rochemont; Georg Bohner; Sebastian Fischer; Alessandra Biondi; Lamiae Grimaldi; Jacques Moret; James Byrne; Laurent Pierot
Journal:  J Neurointerv Surg       Date:  2021-09-07       Impact factor: 8.572

5.  Increased rupture risk in small intracranial aneurysms associated with methamphetamine use.

Authors:  Dylan Noblett; Lotfi Hacein-Bey; Ben Waldau; Jordan Ziegler; Brian Dahlin; Jennifer Chang
Journal:  Interv Neuroradiol       Date:  2020-09-23       Impact factor: 1.610

6.  Safety and Efficacy of the Woven EndoBridge Device for Treatment of Ruptured Intracranial Aneurysms: A Systematic Review and Meta-analysis.

Authors:  M A Essibayi; G Lanzino; W Brinjikji
Journal:  AJNR Am J Neuroradiol       Date:  2021-06-11       Impact factor: 4.966

7.  Aneurysm treatment with WEB in the cumulative population of two prospective, multicenter series: 3-year follow-up.

Authors:  Laurent Pierot; Istvan Szikora; Xavier Barreau; Markus Holtmannspoetter; Laurent Spelle; Denis Herbreteau; Jens Fiehler; Vincent Costalat; Joachim Klisch; Anne-Christine Januel; Werner Weber; Thomas Liebig; Luc Stockx; Joachim Berkefeld; Jacques Moret; Andy Molyneux; James Byrne
Journal:  J Neurointerv Surg       Date:  2020-06-12       Impact factor: 5.836

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.